SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Lindquist Johan 1970 ) "

Sökning: WFRF:(Lindquist Johan 1970 )

  • Resultat 1-10 av 15
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Welén, Karin, 1970, et al. (författare)
  • A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome : No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
  • 2022
  • Ingår i: European Urology. - : Elsevier. - 0302-2838 .- 1873-7560. ; 81:3, s. 285-293
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Men are more severely affected by COVID-19. Testosterone may influence SARS-CoV-2 infection and the immune response.Objective: To clinically, epidemiologically, and experimentally evaluate the effect of antiandrogens on SARS-CoV-2 infection.Designs, settings, and participants: A randomized phase 2 clinical trial (COVIDENZA) enrolled 42 hospitalized COVID-19 patients before safety evaluation. We also conducted a population-based retrospective study of 7894 SARS-CoV-2–positive prostate cancer patients and an experimental study using an air-liquid interface three-dimensional culture model of primary lung cells.Intervention: In COVIDENZA, patients were randomized 2:1 to 5 d of enzalutamide or standard of care.Outcome measurements: The primary outcomes in COVIDENZA were the time to mechanical ventilation or discharge from hospital. The population-based study investigated risk of hospitalization, intensive care, and death from COVID-19 after androgen inhibition.Results and limitations: Enzalutamide-treated patients required longer hospitalization (hazard ratio [HR] for discharge from hospital 0.43, 95% confidence interval [CI] 0.20–0.93) and the trial was terminated early. In the epidemiological study, no preventive effects were observed. The frail population of patients treated with androgen deprivation therapy (ADT) in combination with abiraterone acetate or enzalutamide had a higher risk of dying from COVID-19 (HR 2.51, 95% CI 1.52–4.16). In vitro data showed no effect of enzalutamide on virus replication. The epidemiological study has limitations that include residual confounders.Conclusions: The results do not support a therapeutic effect of enzalutamide or preventive effects of bicalutamide or ADT in COVID-19. Thus, these antiandrogens should not be used for hospitalized COVID-19 patients or as prevention for COVID-19. Further research on these therapeutics in this setting are not warranted.Patient summary: We studied whether inhibition of testosterone could diminish COVID-19 symptoms. We found no evidence of an effect in a clinical study or in epidemiological or experimental investigations. We conclude that androgen inhibition should not be used for prevention or treatment of COVID-19.
  •  
2.
  • Welen, Karin, et al. (författare)
  • COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
  • 2021
  • Ingår i: Trials. - : Springer Science and Business Media LLC. - 1745-6215. ; 22:1
  • Tidskriftsartikel (refereegranskat)abstract
    • The main goal of the COVIDENZA trial is to evaluate if inhibition of testosterone signalling by enzalutamide can improve the outcome of patients hospitalised for COVID-19. The hypothesis is based on the observation that the majority of patients in need of intensive care are male, and the connection between androgen receptor signalling and expression of TMPRSS2, an enzyme important for SARS-CoV-2 host cell internalization.Hospitalised COVID-19 patients will be randomised (2:1) to enzalutamide plus standard of care vs. standard of care designed to identify superiority.Included participants, men or women above 50 years of age, must be hospitalised for PCR confirmed COVID-19 symptoms and not in need of immediate mechanical ventilation. Major exclusion criteria are breast-feeding or pregnant women, hormonal treatment for prostate or breast cancer, treatment with immunosuppressive drugs, current symptomatic unstable cardiovascular disease (see Additional file 1 for further details). The trial is registered at Umeå University Hospital, Region Västerbotten, Sweden and 8 hospitals are approved for inclusion in Sweden.Patients randomised to the treatment arm will be treated orally with 160 mg (4x40 mg) enzalutamide (Xtandi®) daily, for five consecutive days. The study is not placebo controlled. The comparator is standard of care treatment for patients hospitalised with COVID-19.The primary endpoints of the study are (time to) need of mechanical ventilation or discharge from hospital as assessed by a clinical 7-point ordinal scale (up to 30 days after inclusion).Randomisation was stratified by center and sex. Each strata was randomized separately with block size six with a 2:1 allocation ratio (enzalutamide + "standard of care": "standard of care"). The randomisation list, with consecutive subject numbers, was generated by an independent statistician using the PROC PLAN procedure of SAS version 9.4 software (SAS Institute, Inc, Cary, North Carolina) BLINDING (MASKING): This is an open-label trial.The trial is designed to have three phases. The first, an exploration phase of 45 participants (30 treatment and 15 control) will focus on safety and includes a more extensive laboratory assessment as well as more frequent safety evaluation. The second prolongation phase, includes the first 100 participants followed by an interim analysis to define the power of the study. The third phase is the continuation of the study up to maximum 600 participants included in total.The current protocol version is COVIDENZA v2.0 as of September 10, 2020. Recruitment started July 29, 2020 and is presently in safety pause after the first exploration phase. Recruitment is anticipated to be complete by 31 December 2021.Eudract number 2020-002027-10 ClinicalTrials.gov Identifier: NCT04475601 , registered June 8, 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
  •  
3.
  • Lindquist, Johan, 1970-, et al. (författare)
  • Authenticity Governance and the Market for Social Media Engagements : The Shaping of Disinformation at the Peripheries of Platform Ecosystems
  • 2024
  • Ingår i: Social Media + Society. - 2056-3051. ; 10:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Social media engagements, such as likes and follows, have become crucial for driving algorithmic recommendations and underpinning platform economies. This has given rise to disinformation industries that focus on the production and sale of engagements, including Instagram followers—a phenomenon we term the “engagement as a service” market. However, this market poses significant challenges for empirical research as its operations remain obscured from the scrutiny of platforms, their users, and researchers alike. In this article, we propose a mixed-methods approach to make visible the relationship between the engagement market and platform governance, the latter of which increasingly aims to moderate account behavior in terms of authenticity and inauthenticity—what we refer to as “authenticity governance.” By developing this approach, we explore the relationship between the engagement market and platform ecosystems through three case studies: (1) engagement market responses to platform governance; (2) the evolution of engagement as a service; and (3) testing the quality of engagement as a service on Instagram. These investigations allow us to comprehend disinformation as an ongoing negotiation between the engagement market and authenticity governance. Overall, our three integrated approaches can help researchers move forward with the empirical study of disinformation markets that operate at the periphery of platform ecosystems. In short, this article presents a methodological outlook for analyzing (in)authentic engagements as a form of disinformation.
  •  
4.
  • Lindquist, Johan, 1970- (författare)
  • Brokers and Brokerage, Anthropology of
  • 2015. - 2
  • Ingår i: International Encyclopedia of Social and Behavioral Science. - Amsterdam : Elsevier. - 9780080970875 ; , s. 870-874
  • Bokkapitel (refereegranskat)
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  • Lindquist, Johan, 1970-, et al. (författare)
  • Moving or Being Moved: The Migration Infrastructure in Transnational Labor Mobility” (流动, 还是被流动: 跨国劳务的基础设施 项 飙 约翰·林德奎斯特)
  • 2019
  • Ingår i: Sociological Review of China. ; 7:6, s. 3-17
  • Tidskriftsartikel (refereegranskat)abstract
    • 内容提要:根据对中国和印度尼西亚劳务输出的长期实地研究,我们观察到,自20世纪90年代末以来, 亚洲跨国劳务的中介过程日益复杂。细密的管理规则、多样的商业中介、发达的交通通信技术、复杂的合 约,构成了“跨国流动的基础设施”,把流动过程程序化,流动变成了“被流动”。流动基础设施呈现“内卷化” 的趋势,即基础设施不断发展,但是这一发展却阻碍了而不是提高了人们的实际流动能力。这解释了为什 么跨国劳动力流动在亚洲许多地区变得更自由,却也更复杂和更昂贵。流动基础设施的概念一方面要求我 们重视流动过程的细微构成,另一方面帮助我们理解这些细节和更大的社会变迁的关系。
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 15
Typ av publikation
tidskriftsartikel (7)
bokkapitel (6)
samlingsverk (redaktörskap) (1)
doktorsavhandling (1)
Typ av innehåll
refereegranskat (14)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Lindquist, Johan, 19 ... (13)
Xiang, Biao (4)
Ahlm, Clas, 1956- (2)
Gisslén, Magnus, 196 ... (2)
Bjartell, Anders (2)
Stranne, Johan, 1970 (2)
visa fler...
Josefsson, Andreas, ... (2)
Överby, Anna K. (2)
Angelin, Martin (2)
Styrke, Johan (2)
Nilsson, Anna C. (2)
Robinsson, David (2)
Buckland, Robert (2)
Repo, Johanna (2)
Lindquist, Elisabeth (2)
Freyhult, Eva, 1979- (1)
Bill-Axelson, Anna (1)
Akre, Olof (1)
Thellenberg-Karlsson ... (1)
Allard, Annika (1)
Fonseca Rodriguez, O ... (1)
Lenman, Annasara, 19 ... (1)
Bremell, Daniel, 197 ... (1)
Jonsson Henningsson, ... (1)
Becker, Miriam (1)
Pauksens, Karlis (1)
Freyhult, Eva (1)
Welén, Karin, 1970 (1)
Rosendal, Ebba (1)
Niward, Katarina (1)
Wagenius, Magnus (1)
Rudolfsson, Stina H. (1)
Fors Connolly, Anne- ... (1)
Ryden, Cecilia (1)
Östholm Balkhed, Åse ... (1)
Welén, Karin (1)
Weltevrede, Esther (1)
Niward, Katarina, 19 ... (1)
Bremell, Daniel (1)
Jonsson Henningsson, ... (1)
Thellenberg Carlsson ... (1)
Balkhed Östholm, Åse (1)
Sen, Atreyee (1)
Kolling, Marie (1)
visa färre...
Lärosäte
Stockholms universitet (13)
Göteborgs universitet (2)
Umeå universitet (2)
Uppsala universitet (2)
Linköpings universitet (2)
Lunds universitet (2)
visa fler...
Karolinska Institutet (1)
visa färre...
Språk
Engelska (14)
Kinesiska (1)
Forskningsämne (UKÄ/SCB)
Samhällsvetenskap (11)
Medicin och hälsovetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy